



US009636255B2

(12) **United States Patent**  
**Haffner et al.**

(10) **Patent No.:** **US 9,636,255 B2**

(45) **Date of Patent:** **May 2, 2017**

(54) **UVEOSCLERAL DRUG DELIVERY  
IMPLANT AND METHODS FOR  
IMPLANTING THE SAME**

(75) Inventors: **David Haffner**, Mission Viejo, CA  
(US); **Kenneth Curry**, Oceanside, CA  
(US)

(73) Assignee: **DOSE MEDICAL CORPORATION**,  
San Clemente, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 1036 days.

(21) Appl. No.: **13/201,423**

(22) PCT Filed: **Feb. 12, 2010**

(86) PCT No.: **PCT/US2010/024128**

§ 371 (c)(1),  
(2), (4) Date: **Mar. 2, 2012**

(87) PCT Pub. No.: **WO2010/093945**

PCT Pub. Date: **Aug. 19, 2010**

(65) **Prior Publication Data**

US 2012/0165933 A1 Jun. 28, 2012

**Related U.S. Application Data**

(60) Provisional application No. 61/152,651, filed on Feb.  
13, 2009.

(51) **Int. Cl.**  
**A61F 2/14** (2006.01)  
**A61F 9/007** (2006.01)

(Continued)

(52) **U.S. Cl.**  
CPC ..... **A61F 9/00781** (2013.01); **A61F 9/0017**  
(2013.01); **A61K 31/00** (2013.01);  
(Continued)

(58) **Field of Classification Search**

CPC ..... A61M 2210/0612; A61L 2430/16; A61F  
9/00781; A61F 9/0017

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,521,210 A 6/1985 Wong  
4,846,793 A 7/1989 Leonard et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 101396335 A 4/2009  
WO WO 01/80825 A2 11/2001

(Continued)

OTHER PUBLICATIONS

International Search Report and Written Opinion in PCT/US2011/  
061967 mailed Jun. 28, 2012. (In 4 Parts due to size of file—Part  
1 of 4—Part 2 of 4—Part 3 of 4—and Part 4 of 4).

(Continued)

*Primary Examiner* — Laura Bouchelle

*Assistant Examiner* — Anh Bui

(74) *Attorney, Agent, or Firm* — Knobbe, Martens,  
Olson & Bear, LLP

(57) **ABSTRACT**

Devices and methods for treating intraocular pressure are disclosed. The devices include drug delivery implants for treating ocular tissue. Optionally, the devices also include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The drug delivery implants can be implanted in ab interno or ab externo procedures.

**23 Claims, 15 Drawing Sheets**

